China, AstraZeneca

AstraZeneca shares fall on report of potential China probe fallout
AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fraud case in the country's pharma sector in years.
AstraZeneca Falls Most Since 2020 as China Probe Fears Mount
AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns over a Chinese probe into the UK drugmaker.
AstraZeneca’s China business under spotlight amid fraud case
AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in China highlights how much value the Anglo-Swedish pharma giant has attached to the country,
AstraZeneca stock tanks over fears of expanding China fraud probe
AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially escalating insurance fraud investigation in China. | AstraZeneca’s stock price dropped by 8.
AstraZeneca’s Global Operations Continue Amidst China Probe
AstraZeneca (GB:AZN) has released an update. AstraZeneca remains committed to delivering its innovative medicines in China despite ongoing
AstraZeneca falls as fraud investigation reportedly expands in China (update)
An insurance fraud investigation linked to AstraZeneca (AZN) expands in China involving dozens of senior executives. Read more here.
Why Is AstraZeneca Stock Sinking On Tuesday?
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
Investopedia on MSN7h
AstraZeneca Shares Slide As Execs in China Face Fraud Investigation
AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an ...
AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investors
AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...
STAT1d
Probe of AstraZeneca executive in China raises questions about company’s tactics
China's investigation of AstraZeneca's top executive in the country is raising questions about the company's tactics there.
AstraZeneca’s Promising Obesity Treatment Advances Justify Buy Rating: Analyst Report
Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price ...
Wall Street Journal1d
AstraZeneca Says Obesity Pill Shows Minimal Side Effects in Early Trial
AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The ...